Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial symbols : Avxl save search
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Published: 2024-03-18 (Crawled : 12:00) - globenewswire.com
AVXL | $3.8 0.0% 2.1M
|
Health Technology
|
| O: 0.0%
H: 0.78%
C: -5.68%
anavex life sciences schizophrenia trial
Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Published: 2024-01-16 (Crawled : 12:30) - globenewswire.com
AVXL | $3.8 0.0% 2.1M
|
Health Technology
|
| O: -0.5%
H: 0.86%
C: 0.34%
anavex life sciences schizophrenia trial
Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows NeurodegenerationSignificant Reduction of Amyloid Beta Biomarkers of Alzheimer’s Pathology
Published: 2023-09-14 (Crawled : 12:30) - biospace.com/
AVXL | $3.8 0.0% 2.1M
|
Health Technology
|
| O: 4.18%
H: 5.14%
C: -0.38%
anavex disease blarcamesine alzheimer’s trial biomarkers anavex®2-73
Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration
Published: 2023-09-14 (Crawled : 12:00) - globenewswire.com
AVXL | $3.8 0.0% 2.1M
|
Health Technology
|
| O: 4.18%
H: 5.14%
C: -0.38%
anavex disease blarcamesine alzheimer’s trial anavex®2-73
Anavex Life Sciences Announces Completion of ANAVEX(®)2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
Published: 2023-06-06 (Crawled : 12:00) - globenewswire.com
AVXL | $3.8 0.0% 2.1M
|
Health Technology
|
| O: 0.44%
H: 1.15%
C: 0.0%
life sciences trial anavex rett syndrome anavex®2-73 phase 2
Parkinson's Disease Clinical Trial Pipeline Space Brims With Novel Emerging Therapies with Over 120 Key Companies Working in the Domain | DelveInsight
Published: 2023-04-19 (Crawled : 15:00) - prnewswire.com
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -3.51%
H: 1.28%
C: 0.74%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.17%
H: 0.2%
C: -0.02%
VTGN | $4.77 1.49% 1.47% 150K
|
Health Technology
|
| O: 0.0%
H: 2.59%
C: -0.49%
DNLI | $15.98 -3.74% -3.88% 1.5M
|
Health Technology
|
| O: -1.11%
H: 1.31%
C: 0.56%
BIVI | News | $0.4874 -0.21% -0.21% 490K
|
Health Technology
|
| O: -0.24%
H: 4.29%
C: 0.49%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.39%
H: 0.4%
C: -0.14%
APTX | $0.061 21.31% 7.8M
|
Health Services
|
| O: 2.05%
H: 13.81%
C: 11.81%
AVXL | $3.8 0.0% 2.1M
|
Health Technology
|
| O: -0.74%
H: 2.73%
C: 1.61%
disease companies parkinson's pipeline space trial
Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
Published: 2023-02-02 (Crawled : 14:00) - biospace.com/
AVXL | $3.8 0.0% 2.1M
|
Health Technology
|
| O: 0.91%
H: 5.59%
C: 2.52%
anavex anavex®2-73 trial rett syndrome
Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial
Published: 2022-12-14 (Crawled : 19:00) - biospace.com/
AVXL | $3.8 0.0% 2.1M
|
Health Technology
|
| O: -0.69%
H: 3.46%
C: 1.73%
trial alzheimer’s anavex phase 2b
Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial for the Treatment of Adult Patients with Rett Syndrome
Published: 2022-02-04 (Crawled : 14:30) - biospace.com/
AVXL | $3.8 0.0% 2.1M
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: 0.0%
anavex treatment anavex®2-73 trial life science phase 3 syndros rett syndrome
ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints for the Treatment of Adult Patients with Rett Syndrome
Published: 2022-02-01 (Crawled : 13:00) - biospace.com/
AVXL | $3.8 0.0% 2.1M
|
Health Technology
|
| O: 1.24%
H: 0.0%
C: -9.51%
anavex treatment trial phase 3 anavex®2-73 syndros rett syndrome
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s DiseaseThe Company anticipates topline data in the second half of 2022
Published: 2021-10-13 (Crawled : 13:00) - biospace.com/
AVXL | $3.8 0.0% 2.1M
|
Health Technology
|
| O: 0.17%
H: 3.65%
C: 2.32%
disease alzheimer phase 2 topline life science phase 2b trial anavex®2-73 anavex alzheimer’s alzheimer's
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial
Published: 2021-06-28 (Crawled : 13:00) - biospace.com/
AVXL | $3.8 0.0% 2.1M
|
Health Technology
|
| O: 20.0%
H: 6.06%
C: -2.83%
phase 2 correlation life science trial anavex®2-73 anavex biomarkers
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease Dementia
Published: 2021-06-28 (Crawled : 12:00) - anavex.com
AVXL | $3.8 0.0% 2.1M
|
Health Technology
|
| O: 20.0%
H: 6.06%
C: -2.83%
disease treatment phase 2 dementia correlation parkinson life science trial anavex®2-73 anavex biomarkers
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Biomarker Correlated with Efficacy Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome
Published: 2021-06-21 (Crawled : 12:00) - biospace.com/
AVXL | $3.8 0.0% 2.1M
|
Health Technology
|
| O: 8.67%
H: 15.75%
C: 4.61%
treatment phase 2 life science trial anavex®2-73 anavex syndros biomarkers rett syndrome
Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease
Published: 2021-06-08 (Crawled : 12:00) - biospace.com/
AVXL | $3.8 0.0% 2.1M
|
Health Technology
|
| O: 4.51%
H: 0.41%
C: -0.46%
disease alzheimer phase 2 life science phase 2b trial anavex®2-73 anavex enroll alzheimer’s alzheimer's disease alzheimer's
Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit
Published: 2021-05-07 (Crawled : 12:00) - anavex.com
AVXL | $3.8 0.0% 2.1M
|
Health Technology
|
| O: -0.35%
H: 1.99%
C: -1.91%
clinical trials life science trial anavex
Anavex Life Sciences Reports the Results of Review by the Independent Data Safety Monitoring Board for its Phase 2/3 Trials of ANAVEX®2-73 in Patients with Rett Syndrome
Published: 2021-04-12 (Crawled : 12:00) - anavex.com
AVXL | $3.8 0.0% 2.1M
|
Health Technology
|
| O: -0.07%
H: 1.17%
C: -8.85%
phase 2 phase 2/3 results life science trial anavex®2-73 anavex syndros rett syndrome
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease
Published: 2021-03-31 (Crawled : 12:00) - anavex.com
AVXL | $3.8 0.0% 2.1M
|
Health Technology
|
| O: 1.92%
H: 7.76%
C: 4.55%
disease alzheimer phase 2 life science phase 2b trial anavex®2-73 anavex alzheimer’s alzheimer's disease alzheimer's
Anavex Life Sciences Reports ANAVEX®2-73 (blarcamesine) featured as a Disease-Modifying Small Molecule in Phase 3 Clinical Trials in a New Publication in Medical Journal titled “Future Avenues for Alzheimer’s Disease Detection and Therapy”
Published: 2021-03-16 (Crawled : 12:00) - biospace.com/
AVXL | $3.8 0.0% 2.1M
|
Health Technology
|
| O: 4.25%
H: 6.08%
C: 4.4%
disease alzheimer clinical trials therapy life science phase 3 trial anavex®2-73 anavex alzheimer’s alzheimer's disease alzheimer's
Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit
Published: 2021-02-19 (Crawled : 12:03) - globenewswire.com
AVXL | $3.8 0.0% 2.1M
|
Health Technology
|
| O: 1.03%
H: 1.49%
C: -1.65%
life science trial anavex
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.